C12N 2720/10011
Birnaviridae
C12N2720/10011 (Birnaviridae) appears on 164 US grants and 158 published applications in this corpus.
Search patents in C12N- Granted patents
- 164
- Published applications
- 158
- Assignees
- 90
- Inventors
- 356
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 3 | 0 |
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 8 | 0 |
| 1998 | 6 | 0 |
| 1999 | 10 | 0 |
| 2000 | 10 | 0 |
| 2001 | 8 | 0 |
| 2002 | 10 | 6 |
| 2003 | 4 | 9 |
| 2004 | 1 | 7 |
| 2005 | 1 | 5 |
| 2006 | 6 | 6 |
| 2007 | 3 | 11 |
| 2008 | 2 | 4 |
| 2009 | 6 | 5 |
| 2010 | 1 | 5 |
| 2011 | 1 | 6 |
| 2012 | 4 | 4 |
| 2013 | 2 | 3 |
| 2014 | 3 | 6 |
| 2015 | 5 | 7 |
| 2016 | 2 | 5 |
| 2017 | 9 | 9 |
| 2018 | 4 | 7 |
| 2019 | 9 | 7 |
| 2020 | 6 | 4 |
| 2021 | 4 | 9 |
| 2022 | 6 | 10 |
| 2023 | 3 | 4 |
| 2024 | 3 | 9 |
| 2025 | 9 | 5 |
| 2026 | 4 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2720/10034Use of virus or viral component as vaccineIndexing code122
- C12N 2720/10022New viral proteins or individual genes, new structural or functional aspects ofIndexing code68
- C12N 2720/10071Demonstrated in vivo effectIndexing code13
- C12N 2720/10023Virus like particles [vlp]Indexing code9
- C12N 2720/10051Methods of production or purification of viral materialIndexing code9
- C12N 2720/10061Methods of inactivation or attenuationIndexing code9
- C12N 2720/10021Viruses as suchIndexing code6
- C12N 2720/10041Use of virus, viral particle or viral elements as a vectorIndexing code3
All 12 subgroupsShow fewer
Recent patents
- Multivalent HVT vector vaccine31 Mar 2026US 12,589,147 B2Intervet Inc.
- Serum free intracellular pathogen vaccine3 Mar 2026US 12,564,626 B2Intervet Inc.
- Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens6 Jan 2026US 12,514,922 B2Intervet Inc.
- Recombinant herpesvirus of turkeys (HVT) and preparation method and use thereof6 Jan 2026US 12,516,353 B2Yangzhou University
- Recombinant viruses and the uses thereof9 Dec 2025US 12,491,242 B2Ceva Sante Animale
- Methods of vaccine administration to salmonids30 Jul 2026US 2026/0216310 A1Zoetis Services LLC
- Recombinant marek's disease virus and uses thereof2 Jul 2026US 2026/0183386 A1Ceva Sante Animale
- Serum free intracellular pathogen vaccine11 Jun 2026US 2026/0158132 A1Intervet Inc.
- Culture method for fish cells and cell culture medium used therein, and oral vaccine for fish22 Jan 2026US 2026/0021174 A1Bio Science Co., Ltd.
- Recombinant Non-Pathogenic Marek's Disease Virus Constructs Encoding Infectious Laryngotracheitis Virus and Infectious Bursal Disease Virus Antigens22 Jan 2026US 2026/0021176 A1Intervet Inc.
Most cited
By later US patents
- DNA-based vaccination of fish162US 5,780,448 AOttawa Civic Hospital Loeb Research · 1998
- Infectious bursal disease virus VP2 fusion protein expressed by baculovirus86US 5,605,827 AThe Ohio State University Research Foundation · 1997
- Solubilization of protein aggregates50US 4,797,474 ABunge (Australia) Pty. Ltd. · 1989
- Compositions for the delivery of antigens45US 5,958,457 AEmisphere Technologies, Inc. · 1999
- Administration of acemannan44US 5,106,616 ACarrington Laboratories, Inc. · 1992